ESC 365 - Silent cerebral microvascular disease and longitudinal risk of cognitive decline in atrial fibrillation

ESC Premium Access

Silent cerebral microvascular disease and longitudinal risk of cognitive decline in atrial fibrillation

Session: Antithrombotic and anticoagulant therapy in special populations

Topic: Anticoagulants

Speaker: Associate Professor Y. Kondo (Chiba, JP)

Event: ESC Congress 2024

Congress Presentation

About the speaker

Associate Professor Yusuke Kondo

Chiba University Graduate School of Medicine, Chiba (Japan)

1 follower

8 more presentations in this session

Direct oral anticoagulants exhibit lower risks of mortality and bleeding compared to vitamin-k antagonists in atrial fibrillation patients on chronic hemodialysis: a meta-analysis

Speaker: Doctor H. Jain (Jodhpur, IN)

Medication adherence and antithrombotic therapy outcomes: insights from a post-hoc analysis of the AFIRE trial

Speaker: Doctor N. Chiba (Sendai, JP)

Impact of differences in body mass index, body surface area and lean body mass on clinical outcomes in patients with atrial fibrillation receiving edoxaban: 4-year follow-up data from ETNA-AF-Europe

Speaker: Professor G. Boriani (Modena, IT)

Haemorrhagic risk in elderly patients with atrial fibrillation that develop low platelet count during direct oral anticoagulant treatment: insights from the ATHERO-AF study.

Speaker: Doctor D. Menichelli (Rome, IT)

The role of anticoagulation in atrial high-rate episodes: a meta-analysis

Speaker: Doctor H. Ahmed (Omaha, US)

Access the full session

Antithrombotic and anticoagulant therapy in special populations

Speakers: Associate Professor Y. Kondo, Doctor H. Jain, Doctor N. Chiba, Professor G. Boriani, Doctor D. Menichelli...

About the event

ESC Congress 2024

30 August - 2 September 2024

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources